<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678572</url>
  </required_header>
  <id_info>
    <org_study_id>PHP-OCM-301</org_study_id>
    <nct_id>NCT02678572</nct_id>
  </id_info>
  <brief_title>Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delcath Systems Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novella Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Delcath Systems Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate two groups of patients who have melanoma that has spread from the
      eye to the liver: one group (50%) will get high-dose chemotherapy delivered specifically to
      the liver, while the other group (50%) will get one of 4 standard best alternative care
      treatments. Patients in each group will get repeating cycles of treatment until the cancer in
      the liver advances and will be followed until death. This study will evaluate the effect of
      the treatments on how long patients live and how long it takes for the cancer to advance or
      respond to the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 3 phases: a screening phase, treatment phase, and follow-up phase.

      Screening Phase: Screening assessments will be conducted within 28 days prior to
      randomization to determine each patient's overall eligibility. These assessments will include
      medical history, physical examination, Eastern Cooperative Oncology Group (ECOG) performance
      status (PS), 12 lead electrocardiogram (ECG), echocardiogram (ECHO), vital signs, full
      hematology and biochemistry, radiologic assessments of disease status, and an evaluation of
      the vasculature compatibility for Percutaneous Hepatic Perfusion (PHP).

      Treatment Phase: Eligible patients will be randomized to treatment with Melphalan/HDS 3.0
      mg/kg Ideal Body Weight (IBW) or Best Alternative Care (BAC) and must begin treatment within
      14 days following randomization. BAC treatment will be: dacarbazine (DTIC); transarterial
      chemoembolization (TACE); ipilimumab; or pembrolizumab, based on each institution's rank
      order of their BAC treatments based on their standard of care (SOC). For Melphalan/HDS
      treatment, patients will receive up to 6 treatments. Each treatment cycle consists of 6 weeks
      with an acceptable delay for another 2 weeks before the next planned treatment to allow for
      recovery of melphalan-related toxicity, if needed. Tumor response will be assessed in both
      cohorts every 12 weeks (+ 2 weeks) until hepatic disease progression. If the patient receives
      only 1 treatment, the disease assessment scans will be conducted 12 weeks after the date of
      the first treatment. The assessment scans will be reviewed by an Independent Review Committee
      (IRC), also referred to as Independent Central Review. At any time when hepatic progressive
      disease (PD) is observed, the patient will be removed from further study treatment.
      Melphalan/HDS treatment will also be discontinued in the event that recovery from treatment
      related toxicity requires more than 8 weeks from last treatment. An end-of-treatment visit
      will be conducted approximately 6 to 8 weeks following the final dose of study treatment.
      Ongoing adverse events (AEs) at the end-of-treatment visit will be followed until the
      severity returns to baseline of CTCAE Grade &lt; 1. The maximum possible duration of the study
      treatment for any patient will be 12 months.

      Follow-up Phase: In the event that disease has not progressed at the end-of-treatment visit,
      disease assessment scans will continue every 12 weeks (+ 2 weeks) until disease progression
      is documented. Patients will be contacted by phone every 6 months for survival status for the
      first two years following the completion of study treatment, then yearly thereafter, until
      death, withdrawal of informed consent or they become lost to follow-up, whichever occurs
      first. Patients will be monitored for two years, following the completion of study treatment,
      for the development of myelodysplasia and secondary leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Patients will be assessed for their survival status from randomization through end of treatment and contacted every 6 months for the first 2 years and yearly thereafter until death.</time_frame>
    <description>Patients will be followed until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as determined by Investigator</measure>
    <time_frame>PFS will be assessed every 10-14 weeks following the start of 1st treatment until there is evidence of disease progression of the tumor.</time_frame>
    <description>Period of time from 1st treatment until the patient's tumor progresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as determined by Investigator</measure>
    <time_frame>ORR will be assessed every 10-14 weeks from the start of 1st treatment and continues until the earlier of either when there is evidence of disease progression or 1 year from 1st treatment.</time_frame>
    <description>The ratio of patients with either a complete or partial response over the total of all patients in a given group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression Free Survival (PFS) as determined by Imaging Core Lab</measure>
    <time_frame>PFS will be assessed every 10-14 weeks following the start of 1st treatment until there is evidence of disease progression of the tumor.</time_frame>
    <description>Period of time from treatment until the patient's tumor progresses</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective Response Rate (ORR) as determined by Imaging Core Lab</measure>
    <time_frame>ORR will be assessed every 10-14 weeks from the start of 1st treatment and continues until the earlier of when there is evidence of disease progression or 1 year from 1st treatment.</time_frame>
    <description>The ratio of patients with either a complete or partial response over the total of all patients in a given group</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic Progression Free Survival (hPFS) as determined by Imaging Core Lab</measure>
    <time_frame>PFS will be assessed every 10-14 weeks following the start of 1st treatment until there is evidence of disease progression of the tumor in the liver.</time_frame>
    <description>Period of time from treatment until the patient's tumor in the liver progresses</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic Objective Response Rate (hORR) as determined by Imaging Core Lab</measure>
    <time_frame>ORR will be assessed every 10-14 weeks from the start of 1st treatment and continues until the earlier of when there is evidence of disease progression in the liver or 1 year from 1st treatment.</time_frame>
    <description>The ratio of patients with either a complete or partial response in the liver over the total of all patients in a given group</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Quality of life will be assessed at screening (up to 28 days before randomization) and at week 6 (or last week of each cycle) and at end of treatment, which is the earlier of either disease progression or 6-8 weeks after the last treatment.</time_frame>
    <description>Using a questionnaire, patients will self-assess how they feel after the treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Labs (Chemistry and Hematology)</measure>
    <time_frame>Clinical labs will be collected up to 14 days before randomization, and for each cycle at day 1, week 2: days 1,4; weeks 3 and 4: day 1, week 6: day 7, and at end of treatment.</time_frame>
    <description>Clinical labs will be monitored to look for evidence of adverse events resulting from study treatment and evaluated for clinical significance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs (blood pressure, heart rate, breathing rate, and temperature)</measure>
    <time_frame>Vital signs will be taken up to 14 days before randomization, and for each cycle at day 1 (throughout the procedure), weeks 2 and 3: day 1; and at end of treatment.</time_frame>
    <description>Vital signs will be monitored to look for evidence of adverse events resulting from study treatment and evaluated for clinical significance.</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG and ECHOs (electrocardiograms and echocardiograms)</measure>
    <time_frame>ECGs and ECHOs will be taken up to 14 days before randomization, and for each cycle at day 1; and at end of treatment.</time_frame>
    <description>ECGs and ECHOs will be monitored to look for evidence of adverse cardiac events resulting from study treatment and evaluated for clinical significance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evidence of Secondary Disease (Leukemia or Myelodysplastic Syndrome)</measure>
    <time_frame>Secondary disease will be assessed from time of randomization, at each visit, and during the follow-up period via phone calls every 6 months for the 1st two years and then yearly thereafter until death.</time_frame>
    <description>These secondary diseases are used to determine if patients develop later disease that can occur in cancer patients and to evaluate if treatment has an effect on when or if it develops.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Blood concentrations will be assessed in the Melphalan/PHP group at each cycle at 10, 20, 30 minutes during the infusion, at 10, 20, 30 minutes during the washout, at 5-10 minutes, 10-60 minutes, 1-3 hours, and 3-6 hours during the post-washout period.</time_frame>
    <description>Patients in the Melphalan/PHP group will have blood drawn at specific time points throughout the procedure and after the procedure to generate composite data to determine the peak concentration of melphalan in the blood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Plasma Concentration vs Time Curve (AUC)</measure>
    <time_frame>Blood concentrations will be assessed in the Melphalan/PHP group at each cycle at 10, 20, 30 minutes during the infusion, at 10, 20, 30 minutes during the washout, at 5-10 minutes, 10-60 minutes, 1-3 hours, and 3-6 hours during the post-washout period.</time_frame>
    <description>Patients in the Melphalan/PHP group will have blood drawn at specific time points throughout the procedure and after the procedure to generate composite data to determine the exposure of melphalan in the blood over time.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Melanoma, Ocular</condition>
  <arm_group>
    <arm_group_label>Melphalan/PHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAC - TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 of 4 options under BAC: TACE (transarterial chemoembolization)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAC - Dacarbazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 of 4 options under BAC: Systemic Dacarbazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAC - Ipilimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 of 4 options under BAC: Systemic Ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAC - Pembrolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 of 4 options under BAC: Systemic Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan (3 mg/kg IBW) with PHP</description>
    <arm_group_label>Melphalan/PHP</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Transarterial chemoembolization is a procedure in which the blood supply to a tumor is blocked (embolized) and chemotherapy is administered directly into the tumor.</description>
    <arm_group_label>BAC - TACE</arm_group_label>
    <other_name>Transarterial Chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Dacarbazine is to be administered at 250 mg/m2 of body surface area/day given IV for 5 days, with treatment repeated every 3 weeks.</description>
    <arm_group_label>BAC - Dacarbazine</arm_group_label>
    <other_name>DTIC-Dome, DTIC, DIC, Imidazole Carboxamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab is to administered at 3 mg/kg IV over 90 minutes every 3 weeks for a total of 4 treatments.</description>
    <arm_group_label>BAC - Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is to be administered at 2 mg/kg as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.</description>
    <arm_group_label>BAC - Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients ≥ 18 years of age.

          2. Patients must weigh ≥ 35 kg (due to possible size limitations with respect to
             percutaneous catheterization of the femoral artery and vein using the Delcath Hepatic
             Delivery System).

          3. 50% or less histologically or cytologically-proven ocular melanoma metastases in the
             parenchyma of the liver.

          4. Disease in the liver must be measurable by computed tomography (CT) and/or magnetic
             resonance imaging (MRI).

          5. Evidence of limited extrahepatic disease on preoperative radiological studies is
             acceptable if the life threatening component of disease is in the liver. Limited
             extrahepatic disease is defined in this protocol as follows: metastasis in bone,
             subcutaneous, lung or lymph nodes that is amenable to resection or radiation and has a
             defined treatment plan. Patients with extra-hepatic tumor burden which does not have a
             defined treatment plan (i.e. monitor or is unable to be resected or radiated) must not
             be included in the trial.

          6. Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of
             the liver) must be performed within 28 days prior to randomization. An MRI of the
             liver is required at screening to validate that CT accurately reflects the extent of
             disease in the liver. For patients with MRI intolerance, a 3-phase liver CT is to be
             done in place of liver MRI.

          7. Patients must not have chemotherapy, radiotherapy, chemoembolization,
             radioembolization, or immunoembolization for their malignancy within 30 days prior to
             treatment and must have recovered from all side effects of therapeutic and diagnostic
             interventions except those listed in Appendix B of the study protocol.

          8. Patients receiving anti programmed cell death protein 1 (PD-1) immunotherapy such as
             pembrolizumab or nivolumab, or human cytotoxic T-lymphocyte antigen 4 blocking
             antibody such as ipilimumab should wait 8 weeks before Melphalan/HDS treatment.

          9. Patients must have an ECOG PS of 0-1 at screening and on the day prior to treatment.

         10. Patients must have adequate hepatic function as evidenced by total serum bilirubin ≤
             1.5 x the upper limit of normal (ULN) and a prothrombin time (PT) within 2 seconds of
             the upper normal limit. Aspartate aminotransferase/alanine aminotransferase (AST/ALT)
             must be ≤ 2.5 x ULN.

         11. Patients must have a platelet count &gt; 100,000/µL, hemoglobin ≥ 10.0 gm/dL, white blood
             cell count (WBC) &gt; 2,000/uL, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, and a
             serum creatinine ≤ 1.5 mg/dL unless the measured creatinine clearance is &gt; 40
             mL/min/1.73 m2.

         12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             (β-human chorionic gonadotropin) within 7 days prior to randomization.

         13. Provided signed informed consent.

        Exclusion Criteria:

          1. Patients with Child-Pugh Class B or C cirrhosis or with evidence of portal
             hypertension by history, endoscopy, or radiologic studies.

          2. Those with New York Heart Association functional classification II, III or IV active
             cardiac conditions, including unstable coronary syndromes (unstable or severe angina,
             recent myocardial infarction), worsening or new-onset congestive heart failure,
             significant arrhythmias and severe valvular disease must be evaluated for risks of
             undergoing general anesthesia.

          3. History or evidence of clinically significant pulmonary disease that precludes the use
             of general anesthesia.

          4. For female patients of childbearing potential (i.e., have had a menstrual period
             within the past 12 months): unwilling or unable to undergo hormonal suppression to
             avoid menstruation during treatment.

          5. For female patients of childbearing potential (i.e. have had a menstrual period within
             the past 12 months): a positive serum pregnancy test (β-human chorionic gonadotropin)
             within 7 days prior to enrollment.

          6. Sexually active females of childbearing potential and sexually active males with
             partners of reproductive potential: unwilling or unable to use appropriate
             contraception from screening until at least 6 months after last administration of
             study treatment.

          7. Lactating women are excluded from study participation.

          8. Patients taking immunosuppressive drugs or who are unable to be temporarily removed
             from chronic anti-coagulation therapy.

          9. Patients with active bacterial infections with systemic manifestations (malaise,
             fever, leucocytosis) are not eligible until completion of appropriate therapy.

         10. Patients with severe allergic reaction to iodine contrast, which cannot be controlled
             by premedication with antihistamines and steroids (because a hepatic angiogram is
             needed for the Delcath system procedure).

         11. Patients with a history of or known hypersensitivity to melphalan or the components of
             the Melphalan/HDS system.

         12. Patients with latex allergy.

         13. Patients with a history of hypersensitivity to heparin or the presence of
             heparin-induced thrombocytopenia.

         14. Patients with a history of bleeding disorders or evidence of intracranial
             abnormalities which would put them at risk for bleeding with anti-coagulation (e.g.,
             strokes, active metastases).

         15. Patients with a history of gastrinoma, hepatic vasculature incompatible with
             perfusion, hepatofugal flow in the portal vein or known unresolved venous shunting.

         16. Known varices at risk of bleeding, including medium or large esophageal or gastric
             varices, or active peptic ulcer.

         17. Patients with prior Whipple's procedure.

         18. Patients with brain metastases or presence of other intracranial lesions at risk for
             bleeding by history or baseline radiologic imaging. Active infection, including
             Hepatitis B and Hepatitis C infection. Patients with anti-hepatitis B core antibody
             (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are
             exception(s).

         19. Uncontrolled endocrine disorders including diabetes mellitus, hypothyroidism, or
             hyperthyroidism.

         20. Received any investigational agent for any indication within 30 days prior to first
             treatment.

         21. Not recovered from side effects of prior therapy to ≤ Grade 1 (according to National
             Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 4.03).
             Certain side effects that are unlikely to develop into serious or life-threatening
             events (e.g. alopecia) are allowed at &gt; Grade 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Zager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara Turner</last_name>
    <phone>212-489-2100</phone>
    <phone_ext>224</phone_ext>
    <email>tturner@delcath.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie A Callahan, RN</last_name>
    <phone>212-489-2100</phone>
    <phone_ext>247</phone_ext>
    <email>lcallahan@delcath.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>19380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Pham, RN</last_name>
      <phone>650-725-9810</phone>
      <email>ppham5@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Karpisek, BS</last_name>
      <phone>813-745-4798</phone>
      <email>adam.karpisek@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Zager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rivka Kahn</last_name>
      <phone>404-778-5037</phone>
      <email>rivka.leah.kahn@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Melinda Yushak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Weist</last_name>
      <phone>773-702-1835</phone>
      <email>mweist@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Matijevich</last_name>
      <phone>773-702-0725</phone>
      <email>kmatijev@bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Melanoma Center at Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Nowakowski, RN</last_name>
      <phone>973-971-5669</phone>
      <email>maureen.nowakowski@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Eric Whitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Levis</last_name>
      <phone>716-845-3477</phone>
      <email>Maria.Levis@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Boris Kuvshinoff II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanoma Research</last_name>
      <phone>919-613-0400</phone>
    </contact>
    <contact_backup>
      <last_name>Shauna Eggertson, RN, BSN</last_name>
      <phone>919-668-3771</phone>
      <email>shauna.eggertson@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Georgia Beasley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>April Salama, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan &quot;Trey&quot; Blazer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Kulesza</last_name>
      <email>Lauren.Kulesza@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>John Harrison Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Hospital Cancer Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Rex, RN</last_name>
      <phone>484-503-4152</phone>
      <email>robyn.rex@sluhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Stacie Dancho, RN</last_name>
      <phone>484-503-4150</phone>
      <email>stacie.dancho@sluhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjiv Agarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Newhall, RN</last_name>
      <phone>215-503-7488</phone>
      <email>tracey.newhall@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carolyn Palumbo, BA</last_name>
      <phone>212-955-9980</phone>
      <email>carolyn.palumbo@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marlana Orloff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Eschelman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Morningstar, RN</last_name>
      <phone>901-484-3089</phone>
      <email>cmorningstar@WESTCLINIC.com</email>
    </contact>
    <investigator>
      <last_name>Evan Glazer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Rodlauer-Kriegl</last_name>
      <phone>+43 (0) 316 385 80169</phone>
      <email>alexandra.rodlauer-kriegl@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Erika Richtig, Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Verhaegen</last_name>
      <phone>+32 (0) 3 821 35 56</phone>
      <email>iris.verhaegen@uza.be</email>
    </contact>
    <investigator>
      <last_name>Pol Specenier, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie De Gussem</last_name>
      <phone>+32 (0) 9 332 40 81</phone>
      <email>annie.degussem@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Vibeke Kruse, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolien Onsea</last_name>
      <phone>+32 (0) 16 340 398</phone>
      <email>jolien.onsea@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Geert Maleux, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Sebag</last_name>
      <phone>(+33) 04 78 78 28 28</phone>
      <email>william.sebag@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Rivoire, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Mastier, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyrine Ezzili</last_name>
      <phone>+33 (0) 1 44 32 46 09</phone>
      <email>cyrine.ezzili@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Piperno-Neumann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Unversitätsmedizin Berlin Comprehensive Cancer Center</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bärbel Hollen</last_name>
      <phone>+49 (0) 30 450 513 484</phone>
      <email>baerbel.hoellen@charite.de</email>
    </contact>
    <investigator>
      <last_name>Sebastian Ochsenreither, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Estor</last_name>
      <phone>+49 (0) 6421 58 62919</phone>
      <email>anna.estor@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Armin Bender, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Starcke</last_name>
      <phone>+49 (0) 941 944 9641</phone>
      <email>ursula.starcke@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Sebastian Haferkamp, Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Endres</last_name>
      <phone>+49 (0) 931 201 267 22</phone>
      <email>endres_s1@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Anja Gesierich, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Riviello</last_name>
      <phone>+39 (0) 2 94 375 488</phone>
      <email>concetta.riviello@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco Cataldo</last_name>
      <email>francesco.cataldo@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Pier Francesco Ferrucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iosune Goicoechea</last_name>
      <phone>+34 (0) 948 255 400</phone>
      <email>igoicoecheg@unav.es</email>
    </contact>
    <investigator>
      <last_name>Salvador Martin Algarra, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tosca</last_name>
      <phone>+34 (0) 93 227 54 00</phone>
      <phone_ext>3297</phone_ext>
      <email>mtosca@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Ana Arance, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Perez</last_name>
      <phone>91 336 82 63</phone>
      <email>jperezy@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Ainara Soria Rivas, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamsyn Meyer</last_name>
      <phone>+41 (0) 44 255 33 40</phone>
      <email>tamsyn.meyer@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Claudio Huembeli</last_name>
      <phone>+41 (0) 44 255 94 95</phone>
      <email>claudio.huembeli@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Reinhard Dummer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Painter</last_name>
      <phone>+44 (0)23 81 205158</phone>
      <email>S.Painter@soton.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Christian Ottensmeier, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjay Gupta, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Wheater, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George's University Hospital of London</name>
      <address>
        <city>London</city>
        <zip>SW17 ORE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Dunne</last_name>
      <phone>+44 (0) 20 8725 2425</phone>
      <email>mdunne@sgul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Gonsalves, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uveal liver PHP hepatic perfusion chemosaturation Delcath</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

